Cytovation AS, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy, announces the successful closing of its Series A financing round, raising a total of NOK 180 million ($20 million).

Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell membrane of tumor cells. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit www.cytovation.com.

https://www.cytovation.com/

Bergen

Cytovation

Cytovation Raises $20 Million In Series A Financing Round To Advance Clinical Development Of Cypep-1, A First-In-Class Targeted Tumor Membrane Immunotherapy

Cytovation Raises $20 Million In Series A Financing Round To Advance Clinical Development Of Cypep-1, A First-In-Class Targeted Tumor Membrane Immunotherapy

Description

Company Information

Funding Insights

Cytovation Raises $20 Million In Series A Financing Round To Advance Clinical Development Of Cypep-1, A First-In-Class Targeted Tumor Membrane Immunotherapy

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information